Stats Chat

Team Ratings for Round 13

The basic method is described on my Department home page.

Here are the team ratings prior to this week’s games, along with the ratings at the start of the season.

Performance So Far

So far there have been 91 matches played, 53 of which were correctly predicted, a success rate of 58.2%.

Here are the predictions for last week’s games.

Predictions for Round 13

Here are the predictions for Round 13. The prediction is my estimated expected points difference with a positive margin being a win to the home team, and a negative margin a win to the away team.

Team Ratings for Round 17

The basic method is described on my Department home page.

Here are the team ratings prior to this week’s games, along with the ratings at the start of the season.

Performance So Far

So far there have been 106 matches played, 71 of which were correctly predicted, a success rate of 67%.

Here are the predictions for last week’s games.

Predictions for Round 17

Here are the predictions for Round 17. The prediction is my estimated expected points difference with a positive margin being a win to the home team, and a negative margin a win to the away team.

It’s a change to have a nice simple correlation vs causation problem. The Herald (from the Telegraph) says

Statins could cut the risk of dying from cancer by up to half, large-scale research suggests. A series of studies of almost 150,000 people found that those taking the cheap cholesterol-lowering drugs were far more likely to survive the disease.

Looking at the conference abstracts,  a big study found a hazard ratio of 0.78 based on about 3000 cancer deaths in women and a smaller study found a hazard ratio of 0.57 based on about half that many prostate cancer deaths (in men, obviously). That does sound impressive, but it is just a correlation. The men in the prostate cancer studies who happened to be taking statins were less likely to die of cancer; the women in the Women’s Health Initiative studies who happened to be taking statins were less likely to die of cancer.

There’s a definite irony that the results come from the Women’s Health Initiative. The WHI, one of the most expensive trials ever conducted, was set up to find out if hormone supplementation in post-menopausal women reduced the risk of serious chronic disease. Observational studies, comparing women who happened to be taking hormones with those who happened not to be, had found strong associations. In one landmark paper, women taking estrogen had almost half the rate of heart attack as those not taking estrogen, and a 22% lower rate of death from cardiovascular causes. As you probably remember, the WHI randomised trials showed no protective effect — in fact, a small increase in risk.

It’s encouraging that the WHI data show the same lack of association with getting cancer that summaries of randomised trials have shown, and that there’s enough data the association is unlikely to be a chance finding. As with estrogen and heart attack there are biochemical reasons why statins could increase survival in cancer. It could be true, but this isn’t convincing evidence.

Maybe someone should do a randomised trial.

From Stuff:

Revolutionary new drugs that could cure terminal cancer should be on the market here within a few years but patients will have to be “super rich” to afford them.

One four-dose treatment of the drug now under clinical trials costs about $140,000 while other ongoing courses can cost hundreds of thousands of dollars

That’s one real possibility, but there are others.

Firstly, the new drugs might not be all that good. After all, we had some of the same enthusiasm about angiogenesis inhibitors in the late 1990s and about selective tyrosine kinase inhibitors a few years later. The new immunotherapies look wonderful, but so far only  for a minority of patients. And we’re seeing their best side now, from trials stopped early for efficacy.

Alternatively, they might be too effective.  The adaptive immune system is kept under the same sort of strict controls as nuclear weapons, and for much the same reason — its ability to turn the battlefield into a lifeless wasteland. The most successful new treatments remove one of the safety checkpoints, and it’s possible that researchers won’t be able to dramatically expand the range of patients treated without producing dangerous collateral damage.

Finally, there’s the happy possibility. If we get evidence that inhibiting PD-1 and other T-cell checkpoints is safe and broadly effective, everyone will want to make inhibitors, and we’ll get competition. Bristol-Myers-Squib has a monopoly on nivolumab, but it doesn’t have a monopoly on immune checkpoint inhibition. This is already happening, as Bruce Booth reports from the ASCO conference

Most major oncology players have abstracts involving PD-1, including Merck, BMS, AZ, Novartis, Roche, and pretty much everyone else.  Other T-cell related targets like CTLA-4, TIM-3, OX-40, and LAG-3 round out the list of frequent mentions

The drugs still won’t be cheap, because each company will need its own clinical trials, but the development risk will be much lower and the margin for rapacious price-gouging narrower, so they won’t be $140000 per patient for very long.

We’ve seen animations of this sort from Darkhorse Analytics before, but this one is special. It shows how to remove unnecessary components from a pie chart to produce something genuinely useful, though, sadly, the procedure doesn’t work for all pie charts.

Click on the picture to start the animation

(via @JennyBryan)

Yes, it’s only Monday, but this one will be hard to beat (from CNN on Twitter, via @albertocairo)

The off-square dividing make this look as if it’s trying to be a pie chart, but it isn’t. Not only are these not percentages of the same thing and so make no sense as a pie, the colour sections aren’t even scaled in proportion to the numbers (whether you look at angle or area).

Each week, we would like to invite readers of Stats Chat to submit nominations for our Stat of the Week competition and be in with the chance to win an iTunes voucher.

Here’s how it works:

• Anyone may add a comment on this post to nominate their Stat of the Week candidate before midday Friday June 5 2015.
• Statistics can be bad, exemplary or fascinating.
• The statistic must be in the NZ media during the period of May 30 – June 5 2015 inclusive.
• Quote the statistic, when and where it was published and tell us why it should be our Stat of the Week.

Next Monday at midday we’ll announce the winner of this week’s Stat of the Week competition, and start a new one.

(more…)

Australia’s climate is weird, even in the relatively habitable bits such as Melbourne, so it makes for interesting graphs. This is going to be another post about aspect ratios and alignment in graphs and how to use them for things other than lying with statistics. (more…)

• Michael LaCour, the researcher accused of faking data in his study on changing opinions about same-sex marriage, has issued a response to the allegations today as he promised. Virginia Hughes at Buzzfeed and  Ivan Oransky at RetractionWatch have stories. I’ve seen a lot of comments about this on Twitter from people who work in empirical social sciences or in ethics. So far I haven’t seen anyone who is convinced by the response.

• There’s story in New York magazine about David Broockman, who found the problems, about the difficulty of reporting suspicions of fraud in research.  ““I think there’s an interesting metaphor between what I went through now and what I went through as a gay teenager,” Broockman says.

• The UK is introducing a ‘legal highs’ ban. The government are using a widely–quoted figure of 97 deaths in the last year due to legal highs.  As Vice.com explains, the figure is bogus in two ways. Firstly, the figure is based on detectable presence of a drug, not on it being even a contributing cause. Secondly and more importantly, the drugs in the majority of these cases were already illegal at the time.

• You’ve probably seen the Washington Post chart of deaths in World Cup construction. Unless you saw it at the original site, you may not have seen the disclaimer above it (emphasis added):

Some of these numbers (like Sochi’s) are third-party estimates, others (like Beijing’s) are based on official numbers that are almost certainly an undercount. And it’s tough to do an apples-to-apples comparison here, since the Qatar estimates include the deaths of all migrant workers after the announcement of Qatar’s successful bid in 2010, while other countries’ figures may only include deaths directly related to, say, stadium construction.

The exploitation of migrant workers isn’t new and it isn’t all Sepp Blatter’s fault. It’s one of the reasons Qatar was regarded as a terrible choice at the time.
Social media tends to spread images out of context, and this can be a problem if you’re trying to be seen as the sort of journalist who cares about facts.

• Far over the horizon in the opposite direction, there’s a former UK TV presenter ,now working in Qatar, who says there have been no construction-related deaths. And that there’s no problem with gay rights either.

The Herald says

Drinking the caffeine equivalent of more than four espressos a day is harmful to health, especially for minors and pregnant women, the European Union food safety agency has said.

“It is the first time that the risks from caffeine from all dietary sources have been assessed at EU level,” the EFSA said, recommending that an adult’s daily caffeine intake remain below 400mg a day.

Deciding a recommended limit was a request of the European Commission, the EU’s executive body, to try to find a Europe-wide benchmark for caffeine consumption.

But regulators said the most worrying aspect was not the espressos and lattes consumed on cafe terraces across Europe, but Red Bull-style energy drinks, hugely popular with the young.

Contrast that with the “Scientific Opinion on the safety of caffeine“ from the EFSA Panel on Dietetic Products, Nutrition, and Allergies (PDF of the whole thing). First, what they were asked for

the EFSA Panel … was asked to deliver a scientific opinion on the safety of caffeine. Advice should be provided on a daily intake of caffeine, from all sources, that does not give rise to concerns about harmful effects to health for the general population and for specific subgroups of the population. Possible interactions between caffeine and other constituents of so-called “energy drinks”, alcohol, synephrine and physical exercise should also be addressed.

and what they concluded (there’s more than 100 pages extra detail if you want it)

Single doses of caffeine up to 200 mg, corresponding to about 3 mg/kg bw for a 70-kg adult are unlikely to induce clinically relevant changes in blood pressure, myocardial blood flow, hydration status or body temperature, to  reduce perceived extertion/effort during exercise or to mask the subjective perception of alcohol intoxication. Daily caffeine intakes from all sources up to 400 mg per day do not raise safety concerns for adults in the general population, except pregnant women. Other common constituents of “energy drinks” (i.e. taurine, D-glucurono-γ- lactone) or alcohol are unlikely to adversely interact with caffeine. The short- and long-term effects of co-consumption of caffeine and synephrine on the cardiovascular system have not been adequately investigated in humans. Daily caffeine intakes from all sources up to 200 mg per day by pregnant women do not raise safety concerns for the fetus. For children and adolescents, the information available is insufficient to base a safe level of caffeine intake. The Panel considers that caffeine intakes of no concern derived for acute consumption in adults (3 mg/kg bw per day) may serve as a basis to derive daily caffeine intakes of no concern for children and adolescents.

Or, in even shorter paraphrase.

<shrugs> If you need a safe level, four cups a day seems pretty harmless in healthy people, and there doesn’t seem to be a special reason to worry about teenagers.